SynthesisNeurosurgical review2025
Efficacy, safety and dose patterns of tranexamic acid in meningioma surgery: a systematic review and updated meta-analysis of randomized controlled trials.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reviewed the efficacy and safety of intravenous administration of tranexamic acid (TXA) in randomized trials involving patients undergoing intracranial meningioma resection surgery, with special emphasis on the effects of different dosages. A comprehensive search was conducted in the following databases: Cochrane, PubMed, Embase, Scopus, Lilacs, and Web of Science. Two reviewers independently screened titles and abstracts, reviewed the full texts and collected data. Efficacy outcomes analyzed included intraoperative blood loss, blood transfusion rate, duration of surgery, and length of hospital stay. The safety outcomes evaluated included postoperative complications such as seizures, thromboembolic events, and hematoma. A subgroup analysis was performed based on the dosage and timing of administration. Six randomized controlled trials (RCTs) were included, covering 881 patients. Meta-analysis of the data demonstrated that the use of TXA resulted in a significant reduction in intraoperative blood loss (Mean Difference [MD] = -270.26 ml, 95% CI [-422.84, -117.67], p < 0.01, I² = 99%), blood transfusion rate (Relative Risk [RR] = 0.60, 95% CI: [0.46, 0.78], p < 0.01, I² = 3%), duration of surgery (MD = -19.76 min, 95% CI: [-41.74, 2.23], p < 0.01, I² = 75%), and length of hospital stay (MD: -0.48 days, 95% CI: [-0.93, -0.04], p < 0.01, I² = 32%). No significant differences were found in the postoperative complications assessed. In the dosage analysis, the preoperative 20 mg/kg regimen, along with the intraoperative maintenance dose of 1 mg/kg/h, was more effective in reducing intraoperative blood loss in the TXA group, although not statistically significant (323.64 ml vs. 145.54 ml, p = 0.29). The administration of TXA in patients undergoing intracranial meningioma resection surgery showed beneficial results in all efficacy outcomes evaluated, without increasing postoperative complications. However, further studies, especially multicenter ones, are needed to confirm our results.
Indexed as
Identifiers
39760793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.